Day Zero Diagnostics Closes $21M Financing

Day Zero Diagnostics

Day Zero Diagnostics, a Boston, MA-based infectious disease diagnostics company, raised $21M in funding.

The round was led by Sands Capital, with participation from BD, Panacea Venture, Hongkou Capital, Triventures and Golden Seeds. As part of the financing, Brooke Story, President of Integrated Diagnostic Solutions at BD, will join the Board of Directors as an observer. To date, Day Zero Diagnostics has raised over $33M in venture capital financing and over $10M in non-dilutive funding.

The company intends to use the funds to complete the product engineering phase of its diagnostic development effort, expand its DZD Lab Services offerings and strengthen its position as a provider of sequencing based diagnostic services to help clinicians address critical infection situations and transmission events.

Led by CEO Jong Lee, Day Zero Diagnostics is developing sequencing-based diagnostic technologies that can identify, within hours, both the species and the antibiotic resistance profile of a bacterial pathogen. The company has developed and validated proprietary methods to rapidly identify pathogen species and drug resistance profiles using high throughput sequencing. These technologies include processes for Ultra-High Enrichment (UHE) of bacterial DNA from complex clinical samples, such as blood, as well as Keynome®, a family of novel machine learning algorithms for identifying pathogen species and predicting antibiotic resistance from whole genomic sequences. The company’s approach allows for the simultaneous testing of a broad range of bacterial species and determination of antibiotic resistance and susceptibility without the need for traditional culture-based workflows.